Oncolytics Biotech (ONCY) Profit After Tax (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Profit After Tax of -$10.5 million for Q3 2025, down 49.57% year-over-year from -$20.8 million in Q3 2024, and down 135.17% quarter-over-quarter from -$4.4 million in Q2 2025.
Oncolytics Biotech (ONCY) Profit After Tax (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Profit After Tax for 17 consecutive years, with -$10.5 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Profit After Tax fell 49.57% year-over-year to -$10.5 million; the TTM figure through Sep 2025 stood at -$25.3 million (down 24.58% YoY), while the FY2025 annual figure was -$28.9 million, down 23.91% from the prior year.
- Profit After Tax slipped to -$10.5 million in Q3 2025 per ONCY's latest filing, from -$4.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$2.9 million in Q4 2023 and bottomed at -$10.5 million in Q3 2025.
- Historically, Profit After Tax has averaged -$5.4 million across 5 years, with a median of -$5.3 million in 2024.
- Annual changes were most pronounced in 2021 — Profit After Tax plunged 537.47% — and 2023, when it soared 53.97%.
- Oncolytics Biotech's Profit After Tax stood at -$6.1 million in 2021, then retreated by 2.48% to -$6.3 million in 2022, then soared by 53.97% to -$2.9 million in 2023, then plunged by 97.85% to -$5.7 million in 2024, then tumbled by 82.32% to -$10.5 million in 2025.
- Business Quant data shows ONCY's Profit After Tax at -$10.5 million in Q3 2025, -$4.4 million in Q2 2025, and -$4.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | -9.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.44 Mn |
| Sep 30, 2025 | -10.46 Mn |
| Jun 30, 2025 | -4.45 Mn |
| Mar 31, 2025 | -4.66 Mn |
| Dec 31, 2024 | -5.74 Mn |
| Sep 30, 2024 | -7.00 Mn |
| Jun 30, 2024 | -5.31 Mn |
| Mar 31, 2024 | -5.12 Mn |
| Dec 31, 2023 | -2.90 Mn |
| Sep 30, 2023 | -7.40 Mn |
| Jun 30, 2023 | -5.54 Mn |
| Mar 31, 2023 | -4.76 Mn |
| Dec 31, 2022 | -6.30 Mn |
| Sep 30, 2022 | -3.38 Mn |
| Jun 30, 2022 | -4.00 Mn |
| Mar 31, 2022 | -5.35 Mn |
| Dec 31, 2021 | -6.15 Mn |
| Sep 30, 2021 | -3.87 Mn |
| Jun 30, 2021 | -5.89 Mn |
| Mar 31, 2021 | -5.08 Mn |